Literature DB >> 12184280

Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension.

Roberto Littera, Giorgio La Nasa, Giorgio Derchi, Maria D Cappellini, Christy Y P Chang, Licinio Contu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12184280     DOI： 10.1182/blood-2002-04-1171

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report.

Authors:  Ismail Hanta; Mesut Demir; Onur Akpinar; Ali Kocabas; Suleyman Ozbek
Journal:  Clin Rheumatol       Date:  2005-06-11       Impact factor: 2.980

3.  Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature.

Authors:  Kamonpun Ussavarungsi; Charles D Burger
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

4.  Response to "efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18.

Authors:  Elizabeth S Klings; Elliott P Vichinsky; Claudia R Morris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

5.  Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up.

Authors:  Giorgio Derchi; Manuela Balocco; Patrizio Bina; Vincenzo Caruso; Domenico G D'Ascola; Roberto Littera; Raffaella Origa; Maria D Cappellini; Gian L Forni
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

6.  Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.

Authors:  Claudia R Morris; Hae-Young Kim; Felicia Trachtenberg; John Wood; Charles T Quinn; Nancy Sweeters; Janet L Kwiatkowski; Alexis A Thompson; Patricia J Giardina; Jeanne Boudreaux; Nancy F Olivieri; John B Porter; Ellis J Neufeld; Elliott P Vichinsky
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

7.  The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model.

Authors:  Weiguo Hu; Richard Jin; Jinyan Zhang; Tao You; Zhihai Peng; Xiaowen Ge; Roderick T Bronson; Jose A Halperin; Joseph Loscalzo; Xuebin Qin
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

8.  Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Authors:  Claudia R Morris; Hae-Young Kim; John Wood; John B Porter; Elizabeth S Klings; Felicia L Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Sylvia T Singer; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Vandana Sachdev; Sandra Larkin; Jung H Suh; Frans A Kuypers; Elliott P Vichinsky
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 9.  Pulmonary hypertension associated with thalassemia syndromes.

Authors:  Dustin R Fraidenburg; Roberto F Machado
Journal:  Ann N Y Acad Sci       Date:  2016-03-23       Impact factor: 5.691

Review 10.  How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders.

Authors:  Evans M Machogu; Roberto F Machado
Journal:  Blood       Date:  2018-09-11       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.